Home
NewsNewsFairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
In a significant move for the reproductive medicine industry, Fairfax Cryobank and IVI RMA North America have officially announced a strategic partnership designed to Fairfax IVI expand donor sperm access. This collaboration seeks to provide individuals and couples with high-quality donor sperm, significant savings, and premium support services as they pursue their family-building goals.
Through this new alliance, IVI RMA North America patients will gain direct access to Fairfax Cryobank’s extensive nationwide network of diverse donors. Beyond increasing the availability of donor sperm, the partnership introduces various programmes aimed at enhancing financial accessibility and overall value for patients. Key benefits include personalised guidance, genetic compatibility insights, and flexible programme options tailored to the unique needs of each family.
To ensure a seamless experience, Fairfax Cryobank will manage the shipping and secure storage of samples while providing dedicated support throughout the process. The integration of these services into IVI RMA’s clinical framework is intended to reduce the logistical and emotional complexities often associated with fertility treatments.
Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America, highlighted the importance of this collaboration for patient care: “This partnership with Fairfax Cryobank is an important advancement in our mission to expand access to high-quality, patient-centred fertility care to all Americans. By combining IVI RMA's clinical expertise with Fairfax Cryobank's high-quality diverse donor sperm and value-added services, we are reducing the financial and emotional barriers to reproductive treatment and empowering more individuals and families to pursue parenthood with greater confidence and clarity.”
The partnership will see Fairfax Cryobank’s donor selection process fully integrated into the personalised fertility treatment plans at IVI RMA’s 27 North American laboratories. This streamlined approach includes coordinated lab services and genetic counselling, allowing patients to make more informed clinical decisions. Furthermore, both organisations have reaffirmed their commitment to inclusive services, supporting LGBTQ+ families, single moms by choice, and any individuals requiring donor sperm to build their families. Dr. Harvey Stern, MD, PhD, Medical Director of Fairfax Cryobank, expressed his pride in the joint effort:
“We are proud to partner with IVI RMA North America to deliver a seamless patient-centred experience for those building their families. By combining our extensive donor network, secure storage, and personalised guidance with IVI RMA's clinical leadership and advanced IVF laboratories, we are ensuring patients receive trusted support at every step of their journey.”
Fairfax Cryobank, established in 1986, is renowned for its comprehensive donor screening and testing procedures, operating seven locations across the United States to serve recipients globally. IVI RMA North America, which includes Reproductive Medicine Associates, Boston IVF, and TRIO, has facilitated the birth of over 220,000 babies to date. As part of IVI RMA Global, the network remains a leader in evidence-based fertility solutions, employing over 6,000 people across 15 countries.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
